Pfizer Raises 2026 Revenue Outlook to $60.5–$62.5B After TUKYSA Approval
PFE sits 20% above its 52-week low of $23.62.
Summary
Pfizer lifted its 2026 revenue outlook to $60.5–$62.5B, up from prior guidance, following FDA approval of TUKYSA as chemo-free maintenance for HER2+ metastatic breast cancer. The approval was already reported on Oct 7, but the raised guidance is new and material. Cantor also raised its price target to $28 from $27, citing the Mevrometostat Mevpro-1 trial as a near-term catalyst. Separately, Pfizer committed to about $70B in U.S. R&D and manufacturing investment, gaining a three-year tariff exemption. The company also joined CMS GLOBE pricing deals, declared a $0.43 Q4 dividend, and will close two Italian production lines. The raised guidance and $70B commitment are the key new facts for traders.
At the time of this announcement, PFE was trading at $28.36 on NYSE in the Life Sciences sector, with a market capitalization of approximately $161.2B. The 52-week trading range was $23.62 to $29.21. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.